Overcoming the Blood–Brain Barrier. Challenges and Tricks for CNS Drug Delivery
Open accessThe DOI matches its Crossref record; 35 of the 35 references it cites were found in a registry or an index.
Abstract
Treatment of certain central nervous system disorders, including different types of cerebral malignancies, is limited by traditional oral or systemic administrations of therapeutic drugs due to possible serious side effects and/or lack of the brain penetration and, therefore, the efficacy of the drugs is diminished. During the last decade, several new technologies were developed to overcome barrier properties of cerebral capillaries. This review gives a short overview of the structural elements and anatomical features of the blood–brain barrier. The various in vitro (static and dynamic), in vivo (microdialysis), and in situ (brain perfusion) blood–brain barrier models are also presented. The drug formulations and administration options to deliver molecules effectively to the central nervous system (CNS) are presented. Nanocarriers, nanoparticles (lipid, polymeric, magnetic, gold, and carbon based nanoparticles, dendrimers, etc.), viral and peptid vectors and shuttles, sonoporation and microbubbles are briefly shown. The modulation of receptors and efflux transporters in the cell membrane can also be an effective approach to enhance brain exposure to therapeutic compounds. Intranasal administration is a noninvasive delivery route to bypass the blood–brain barrier, while direct brain administration is an invasive mode to target the brain region with therapeutic drug concentrations locally. Nowadays, both technological and mechanistic tools are available to assist in overcoming the blood–brain barrier. With these techniques more effective and even safer drugs can be developed for the treatment of devastating brain disorders.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
1 retracted
Foust, K. D., Wang, X., McGovern, V. L., Braun, L., Bevan, A. K., Haidet, A. M., Le, T. T., Morales, P. R., Rich, M. M., Burghes, A. H. M., et al. (2010) · Nature Biotechnology · doi:10.1038/nbt.1610 · Cited by 688
RetractedAstrocyte-endothelial interactions at the blood-brain barrier
Abbott, N. J., Rönnbäck, L., & Hansson, E. (2006) · Nature Reviews Neuroscience · doi:10.1038/nrn1824 · Cited by 5,595
Structure and function of the blood–brain barrier
Abbott, N. J., Patabendige, A. A. K., Dolman, D. E. M., Yusof, S. R., & Begley, D. J. (2010) · Neurobiology of Disease · doi:10.1016/j.nbd.2009.07.030 · Cited by 5,185
A perivascular origin for mesenchymal stem cells in multiple human organs
Crisan, M., Yap, S., Casteilla, L., Chen, C.-W., Corselli, M., Park, T. S., Andriolo, G., Sun, B., Zheng, B., Zhang, L., et al. (2008) · Cell Stem Cell · doi:10.1016/j.stem.2008.07.003 · Cited by 3,991 · cited 1×
“Similar multipotential stem cell activity has been exhibited in CNS microvascular cells to that seen in MSCs and also pericytes and MSCs express many of the same cell surface markers [48].”
BackgroundKettenmann, H., Hanisch, U.-K., Noda, M., & Verkhratsky, A. (2011) · Physiological Reviews · doi:10.1152/physrev.00011.2010 · Cited by 3,547 · cited 1×
“Microglial activation in response to pathophysiological stressors can trigger changes in cell morphology, which include reduced complexity of cellular processes and transition from a ramified morphology to an amoeboid appearance [19].”
BackgroundThe effect of particle design on cellular internalization pathways
Gratton, S. E. A., Ropp, P. A., Pohlhaus, P. D., Luft, J. C., Madden, V. J., Napier, M. E., & DeSimone, J. M. (2008) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0801763105 · Cited by 2,918 · cited 1×
“with particle replication in non-wetting templates (PRINT) micro- and nanoparticles [76,77].”
MethodThe blood-brain barrier/neurovascular unit in health and disease
Hawkins, B. T., & Davis, T. P. (2005) · Pharmacological Reviews · doi:10.1124/pr.57.2.4 · Cited by 2,661
The Effect of Nanoparticle Size on In Vivo Pharmacokinetics and Cellular Interaction
Hoshyar, N., Gray, S., Han, H., & Bao, G. (2016) · Nanomedicine · doi:10.2217/nnm.16.5 · Cited by 1,990 · cited 1×
“The optimal size of a NP also depends on the specific location and type of targeted tissue [70], for example, most tumors have a vascular pore cutoff size between 380 and 780 nm [71].”
BackgroundIntravascular AAV9 preferentially targets neonatal neurons and adult astrocytes
Foust, K. D., Nurre, E., Montgomery, C. L., Hernandez, A., Chan, C. M., & Kaspar, B. K. (2009) · Nature Biotechnology · doi:10.1038/nbt.1515 · Cited by 1,456 · cited 1×
“[143] AAV9 vectors are well tolerated IV viral vectors that can cross the endothelial cells of the BBB [144,145] via active-transport, while not compromising barrier integrity [146] and have promising results in clinical trials for their safety and their efficiency to transduce target cells, for example, in spinal mus…”
BackgroundTransvascular delivery of small interfering RNA to the central nervous system
Kumar, P., Wu, H., McBride, J. L., Jung, K.-E., Hee Kim, M., Davidson, B. L., Kyung Lee, S., Shankar, P., & Manjunath, N. (2007) · Nature · doi:10.1038/nature05901 · Cited by 1,246
Intranasal delivery of biologics to the central nervous system
Lochhead, J. J., & Thorne, R. G. (2012) · Advanced Drug Delivery Reviews · doi:10.1016/j.addr.2011.11.002 · Cited by 1,214
Helms, H. C., Abbott, N. J., Burek, M., Cecchelli, R., Couraud, P.-O., Deli, M. A., Förster, C., Galla, H. J., Romero, I. A., Shusta, E. V., et al. (2016) · Journal of Cerebral Blood Flow & Metabolism · doi:10.1177/0271678x16630991 · Cited by 843
Boosting Brain Uptake of a Therapeutic Antibody by Reducing Its Affinity for a Transcytosis Target
Yu, Y. J., Zhang, Y., Kenrick, M., Hoyte, K., Luk, W., Lu, Y., Atwal, J., Elliott, J. M., Prabhu, S., Watts, R. J., et al. (2011) · Science Translational Medicine · doi:10.1126/scitranslmed.3002230 · Cited by 794 · cited 1×
“First, IgG was studied as a peptide shuttle, targeted against insulin and transferrin receptors [161] but was found to be unsuccessful due to its high affinity, which decreased the efficiency of the drug release [162,163].”
BackgroundApolipoprotein E and Apolipoprotein E Receptors: Normal Biology and Roles in Alzheimer Disease
Holtzman, D. M., Herz, J., & Bu, G. (2012) · Cold Spring Harbor Perspectives in Medicine · doi:10.1101/cshperspect.a006312 · Cited by 782 · cited 1×
“Song and coworkers have constructed an ApoE-containing high density lipoprotein (HDL) inspired nanocarrier [89], which is BBB permeable [90] and has high Aβ-binding affinity [91], for the treatment of Alzheimer’s disease (AD).”
BackgroundA new blood–brain barrier model using primary rat brain endothelial cells, pericytes and astrocytes
Nakagawa, S., Deli, M. A., Kawaguchi, H., Shimizudani, T., Shimono, T., Kittel, Á., Tanaka, K., & Niwa, M. (2009) · Neurochemistry International · doi:10.1016/j.neuint.2008.12.002 · Cited by 728 · cited 1×
“Panel A [50], B [51], C [52], D [53], E [54].”
Davidson, B. L., Stein, C. S., Heth, J. A., Martins, I., Kotin, R. M., Derksen, T. A., Zabner, J., Ghodsi, A., & Chiorini, J. A. (2000) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.97.7.3428 · Cited by 531 · cited 1×
“Furthermore, the different serotypes have preferences in cell types: AAV4 primarily targets ependymal cells [230], AAV8 tranduces astrocytes, microglia, and oligodendrocytes the most, and AAV9 had the greatest tropism for neurons [226].”
Aschauer, D. F., Kreuz, S., & Rumpel, S. (2013) · PLoS ONE · doi:10.1371/journal.pone.0076310 · Cited by 522 · cited 1×
“Furthermore, the different serotypes have preferences in cell types: AAV4 primarily targets ependymal cells [230], AAV8 tranduces astrocytes, microglia, and oligodendrocytes the most, and AAV9 had the greatest tropism for neurons [226].”
BackgroundDisrupting the blood–brain barrier by focused ultrasound induces sterile inflammation
Kovacs, Z. I., Kim, S., Jikaria, N., Qureshi, F., Milo, B., Lewis, B. K., Bresler, M., Burks, S. R., & Frank, J. A. (2017) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1614777114 · Cited by 458
Astrocytes in physiological aging and Alzheimer’s disease
Rodríguez-Arellano, J. J., Parpura, V., Zorec, R., & Verkhratsky, A. (2016) · Neuroscience · doi:10.1016/j.neuroscience.2015.01.007 · Cited by 439 · cited 1×
“Astrocytes are glial cells that help, support and protect neurons by controlling neurotransmitter and ion concentrations to maintain the homeostatic balance of the neural microenvironment, by modulating synaptic transmission and by regulating immune reactions [16] and by interacting with endothelial cells through thei…”
BackgroundVieira, D., & Gamarra, L. (2016) · International Journal of Nanomedicine · doi:10.2147/ijn.s117210 · Cited by 427
Current approaches to enhance CNS delivery of drugs across the brain barriers
Lu, C.-T., Zhao, Y.-Z., Wong, H. L., Cai, J., Peng, L., & Tian, X.-Q. (2014) · International Journal of Nanomedicine · doi:10.2147/ijn.s61288 · Cited by 350
Vorbrodt, A. W., & Dobrogowska, D. H. (2003) · Brain Research Reviews · doi:10.1016/s0165-0173(03)00177-2 · Cited by 293 · cited 1×
“AJs are composed of multiple protein components including vascular endothelium (VE) cadherin, actin, nectin, and catenin [15].”
BackgroundZhang, H., Yang, B., Mu, X., Ahmed, S. S., Su, Q., He, R., Wang, H., Mueller, C., Sena-Esteves, M., Brown, R., et al. (2011) · Molecular Therapy · doi:10.1038/mt.2011.98 · Cited by 291
Joshi, S. A., Chavhan, S. S., & Sawant, K. K. (2010) · European Journal of Pharmaceutics and Biopharmaceutics · doi:10.1016/j.ejpb.2010.07.007 · Cited by 235 · cited 1×
“PBCA 145–250 negative [133] PLA 10–100 [120]”
Brain targeting of nerve growth factor using poly(butyl cyanoacrylate) nanoparticles
Kurakhmaeva, K. B., Djindjikhashvili, I. A., Petrov, V. E., Balabanyan, V. U., Voronina, T. A., Trofimov, S. S., Kreuter, J., Gelperina, S., Begley, D., & Alyautdin, R. N. (2009) · Journal of Drug Targeting · doi:10.1080/10611860903112842 · Cited by 221 · cited 1×
“PBCAs are usually targeted to low density lipoprotein (LDL) receptors to make them pass the BBB in mouse and rat models and deliver neural growth factor (NGF) [99] or Tacrine (also delivered by Chitosan carriers) [100] into the CNS as a drug for Alzheimer’s and Parkinson’s disease therapy.”
BackgroundYang, B., Li, S., Wang, H., Guo, Y., Gessler, D. J., Cao, C., Su, Q., Kramer, J., Zhong, L., Ahmed, S. S., et al. (2014) · Molecular Therapy · doi:10.1038/mt.2014.68 · Cited by 213 · cited 1×
“[143] AAV9 vectors are well tolerated IV viral vectors that can cross the endothelial cells of the BBB [144,145] via active-transport, while not compromising barrier integrity [146] and have promising results in clinical trials for their safety and their efficiency to transduce target cells, for example, in spinal mus…”
BackgroundGlutamate-Mediated Blood-Brain Barrier Opening: Implications for Neuroprotection and Drug Delivery
Vazana, U., Veksler, R., Pell, G. S., Prager, O., Fassler, M., Chassidim, Y., Roth, Y., Shahar, H., Zangen, A., Raccah, R., et al. (2016) · Journal of Neuroscience · doi:10.1523/jneurosci.0587-16.2016 · Cited by 205 · cited 2×
“In addition, neuronal activation, using highintensity magnetic stimulation, increases barrier permeability and facilitates drug delivery [211].”
BackgroundYang, T., Fogarty, B., LaForge, B., Aziz, S., Pham, T., Lai, L., & Bai, S. (2017) · The AAPS Journal · doi:10.1208/s12248-016-0015-y · Cited by 204
Wang, D., El-Amouri, S. S., Dai, M., Kuan, C.-Y., Hui, D. Y., Brady, R. O., & Pan, D. (2013) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1222742110 · Cited by 159 · cited 2×
“LDLR targeting natural protein ligands, such as ApoB, ApoE fragments [173,174], and Angiopep-2, are widely used as a drug delivery peptide shuttle [170].”
BackgroundMerkel, S. F., Andrews, A. M., Lutton, E. M., Mu, D., Hudry, E., Hyman, B. T., Maguire, C. A., & Ramirez, S. H. (2017) · Journal of Neurochemistry · doi:10.1111/jnc.13861 · Cited by 132
McCarty, D. M., DiRosario, J., Gulaid, K., Muenzer, J., & Fu, H. (2009) · Gene Therapy · doi:10.1038/gt.2009.85 · Cited by 105 · cited 2×
“[143] AAV9 vectors are well tolerated IV viral vectors that can cross the endothelial cells of the BBB [144,145] via active-transport, while not compromising barrier integrity [146] and have promising results in clinical trials for their safety and their efficiency to transduce target cells, for example, in spinal mus…”
BackgroundUltrasonically triggered drug delivery: Breaking the barrier
Husseini, G. A., Pitt, W. G., & Martins, A. M. (2014) · Colloids and Surfaces B: Biointerfaces · doi:10.1016/j.colsurfb.2014.07.051 · Cited by 87
Zhang, X., He, T., Chai, Z., Samulski, R. J., & Li, C. (2018) · Biomaterials · doi:10.1016/j.biomaterials.2018.05.041 · Cited by 65 · cited 1×
“THR also directly binds to AAV8 viral vector and facilitates its crossing through the BBB [181].”
BackgroundPericytes from mesenchymal Stem cells as a model for the blood-brain barrier
Tian, X., Brookes, O., & Battaglia, G. (2017) · Scientific Reports · doi:10.1038/srep39676 · Cited by 56 · cited 1×
“Recent work has shown strong similarities between MSCs and pericytes [47].”
ResultAAV Provides an Alternative for Gene Therapy of the Peripheral Sensory Nervous System
Beutler, A. S. (2010) · Molecular Therapy · doi:10.1038/mt.2010.41 · Cited by 19 · cited 1×
“This method can provide long-term expression of the transgene in non-dividing cells, especially with adeno-associated viral (AAV) vectors [141].”
Method
Cited by
Current Strategies to Enhance Delivery of Drugs across the Blood–Brain Barrier
Teleanu, R. I., Preda, M. D., Niculescu, A.-G., Vladâcenco, O., Radu, C. I., Grumezescu, A. M., & Teleanu, D. M. (2022) · Pharmaceutics · doi:10.3390/pharmaceutics14050987 · Cited by 200
Microglia-targeting nanotherapeutics for neurodegenerative diseases
Zhao, N., Francis, N. L., Calvelli, H. R., & Moghe, P. V. (2020) · APL Bioengineering · doi:10.1063/5.0013178 · Cited by 104
Wang, L., Shi, Y., Jiang, J., Li, C., Zhang, H., Zhang, X., Jiang, T., Wang, L., Wang, Y., & Feng, L. (2022) · Small · doi:10.1002/smll.202203678 · Cited by 71
Alzheimer’s disease and drug delivery across the blood–brain barrier: approaches and challenges
Iqbal, I., Saqib, F., Mubarak, Z., Latif, M. F., Wahid, M., Nasir, B., Shahzad, H., Sharifi-Rad, J., & Mubarak, M. S. (2024) · European Journal of Medical Research · doi:10.1186/s40001-024-01915-3 · Cited by 60
Yang, J., Luly, K. M., & Green, J. J. (2023) · WIREs Nanomedicine and Nanobiotechnology · doi:10.1002/wnan.1853 · Cited by 40
Metadata
- Authors
- Bors, L. A., & Erdő, F.
- Venue
- Scientia Pharmaceutica
- Publisher
- MDPI AG
- Published
- 2019-02-28
- Volume
- 87
- Issue
- 1
- Pages
- 6
- ISSN
- 0036-8709 (ISSN-L)
- 2218-0532
- OpenAlex
- W2918272013
- Cited by
- 252
- References
- 35
- FWCI
- 9.16
- Type
- journal article
- Language
- en
- Open access
- gold
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.